Traumatic Brain Injury

A paradigm shift in the treatment of TBI

Post Concussion Syndrome (PCS)

Advancing solutions that intervene in the processes leading to PCS

Concussion

Seeking solutions that directly impact the development of chronic traumatic encephalopathy (CTE)

Other Neurological Conditions

Targeting methods to improve the treatment of certain aspects of stroke

About PresSura Neuro

PresSura Neuro is a biopharmaceutical company, developing unique therapeutics for the treatment of:

  • The effects of severe traumatic brain injury (TBI)
  • The effects from concussions including chronic traumatic encephalopathy (CTE) and post concussion syndrome (PCS)
  • Stroke
  • Other neurological conditions

PresSura Neuro is targeting conditions that currently have no regulatory approved medications

Corporate Background

PresSura Neuro is the trading name for Eustralis Pharmaceuticals Ltd and is based in Collins Street in Melbourne, Australia. The company was first formed in 2005 and has licensed compounds from Hoffman-La Roche (Switzerland) to develop solutions for neurological indications for which there are currently no treatments. All PresSura’s drug development programs target unmet neurological needs.

The Science

The lead research scientist behind the indications that PresSura is developing is Dr Robert Vink.  He is currently Pro Vice Chancellor for the University of South Australia’s Division of Health Sciences.  Dr Vink is one of the leading opinion leaders in the world in the field of TBI, brain trauma and concussion/CTE research. He is an original founder of the company and also served as a director of the company up until late 2017. He continues his engagement with the company through  providing consulting services as required around these indications.

Team

Board of Directors

PETER PURSEY AM

Peter Pursey is experienced in corporate governance, senior executive management, leadership, capital raising and strategic planning. He has served on a number of public company and ASX listed company boards as a director, chairman and executive chairman. He has extensive experience in the mining services, energy storage and medical diagnostics industry sectors.

 


PETER HIGGINS

Peter Higgins is an experienced manager, business leader and investor. He has supported the company in its development and is a very valuable member of the board.

 


Key Management

PETER PURSEY AM

Chief Executive Officer Peter is an experienced senior executive and has lead the development and strategic direction and strategy of the company for over 6 years. The PresSura team now comprises leading scientists and drug development personnel from all over the world. His extensive network extends to global leaders in all phases of drug development, regulatory, pricing and marketing experts.


peter.pursey@pressuraneuro.com

JOHN PERIERA

John Pereira has over 30 years experience in investment banking, funds management, law and as a business founder. He is a highly experienced corporate advisor particularly with emerging bio-tech companies. Mr Pereira is the founder and MD of Tristar Corporate Advisors and Principal of Periera Partners Lawyers and Consultants.

 


JOHN HIGGINS

John is an experienced businessman with extensive experience in the international business environment. He holds chair and director appointments across a number of business industry sectors in Australia and overseas.

 


Head of Drug Development

DR PIERRE VANKAN

Dr Vankan was a global project leader and lifecycle leader in Hoffman-La Roche for 10 years and has extensive experience in drug development and the implementation of drug development plans from pre-clinical through to Phase 3 clinical trials. He was Head of Development of Santhera Pharmaceuticals in Switzerland before commencing his own consulting business. Pierre has led the drug development programs in the company over the last 5 years and was associated with the company for some years before taking up his current appointment. Pierre has a very extensive global network across every sector of the drug development industry.

PresSura Neuro Science and Technology Development

PresSura is developing unique therapeutics for the treatment of a number of neurological conditions. The company has completed the full scale manufacture of its compounds to GMP standard for the treatment of TBI and concussion related conditions.

Severe and Moderate Traumatic Brain Injury

PresSura is targeting the control of intercranial pressure (ICP) to prevent injury caused by brain swelling. All preclinical and Phase 1
development has been completed and an international Phase 2 program will commence early in 2018. Success in this development is expected to result in a paradigm shift in the treatment of ICP in many brain-injury related conditions.

Concussion Related Conditions

Concussive injuries are closely tied to athletes who participate in contact sports like football, soccer, professional wrestling, boxing and hockey, as well as military service men and women who sustain concussive head injuries.

PresSura has identified methods that may interfere with the development of processes leading to Post Concussion Syndrome (PCS) and the cascade leading to Chronic Traumatic Encephalopathy (CTE) in humans. The company has completed all the preclinical and Phase 1 development for these conditions and is currently planning for a follow on Phase 2 development program.

Stroke and Other Neurological Conditions

PresSura is developing methods to target aspects of the neurological conditions associated with some forms of stroke.

 

Partnering

PresSura Neuro works with numerous high end partners and affiliates who are leaders in their field.
Some of our key partners and collaborators include:

Get In Touch Today

PresSura Neuro

Level 2, 470 Collins Street, Melbourne, Victoria, 3000, Australia
Email: info@pressuraneuro.com

Find Us – View Map

Enquire Now!

If you would like to ask a question or have a general enquiry
please contact us by completing the form below.

Safe Harbour Statement, Disclaimer, Disclosures

This website (including all documents, graphs, media files, reports and others, herein) was prepared for Eustralis Pharmaceuticals Limited (ACN: 114 270 727) herein the company or PresSura. PresSura Neuro Limited is the trading name of Eustralis Pharmaceuticals Limited. This document is not an invitation to purchase shares or other securities in the company. No part of this website shall be used to present the company to any person with the intention of offering shares or other securities in the company. Although care has been taken to accuracy represent the company, the company, its directors and agents do not guarantee the accuracy of information presented on this website. The company, its directors and agents take no responsibility and shall not carry any liabilities arising from the use of information presented on this website.

This website may contain forward-looking statements with respect to PresSura’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of PresSura and information currently available to the company. PresSura cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. PresSura has no obligation to update the statements contained in this website,/ unless required by law.